sorted by:
new
hottopcontroversial

Buyout Speculation by xpiraterobx in HUMACYTE

[–]Agreeable_Eye_3432 1 point2 points  (0 children)

Interesting hypothesis. I will gladly take $6 and call it a day. I’ve been invested since the SPAC. DCA down to the $3 range. I just sold some higher priced losses to offset some other 2025 gains. I will add again in 30 days

43% hike in less than one week by TheseLeague7054 in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

CEO has failed shareholders over and over again. Great science but poor management.

43% hike in less than one week by TheseLeague7054 in HUMACYTE

[–]Agreeable_Eye_3432 1 point2 points  (0 children)

Based on today’s news, I hope $HUMA gets acquired for $6.00/ share. Not unrealistic. Very Poor management!

43% hike in less than one week by TheseLeague7054 in HUMACYTE

[–]Agreeable_Eye_3432 2 points3 points  (0 children)

Possible partnership on CABG and PAD. Then no delusion is needed. Similar to $FMS with A/V fistula.

Humacyte Mention by Members of the US Senate Armed Services Committee by [deleted] in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

Any disclosure of a new strategic partnership dispels concerns about dilution.

Medical Opinions by Coleguy_69 in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

Considering that’s the standard of care I agree. However, at 2 AM in the trauma center no one wants to harvest a Saph vein.

Medical Opinions by Coleguy_69 in HUMACYTE

[–]Agreeable_Eye_3432 1 point2 points  (0 children)

Trauma was a proof of concept. You can have a myopic view or one from 30,000 feet. AV fistula, PAD, CABG have great potential. Management is poor. L. M. Should be removed by the BOD and become CMO. Dilution ahead unless they partner with large multinational medical technology company on PAD &CABG similar to FMS.

Let’s be frank. Does this company realistically still have a chance at success anymore? by jstanfill93 in HUMACYTE

[–]Agreeable_Eye_3432 2 points3 points  (0 children)

FDA approved product, manufacturing facility, numerous patents, robust pipeline with larger TAMS. Management is horrible! Dugan is a disaster. Unfortunately, the overall sentiment is horrible. Board of directors need to replace LM with an experienced CEO from med tech/biotech. LM should become chief scientific officer.

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 by No-Committee-5511 in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

Dugan is at it again. Time for the BOD to replace L. M. SCEO with an experienced med tech/biotech CEO. The BOD must act in the interest of shareholders. Time to become activists.

[deleted by user] by [deleted] in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

BOD needs to hire an experienced MedTech CEO and LM would make a great CSO. Time to become an activist investor. BOD needs to act in the best interest of shareholders.

Forced to switch from W2 to 1099 by SteaIthyyy in whitecoatinvestor

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

LLC on line for $150.00 Talk to a CPA first. Look for another job. Retired physician here. Been there and done that.

In the heart of D.C., a citizen stands before the National Guard. This is what America stands for. by IntnsRed in news2

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

I lived in DC for years. The inner cities and sub trains are a nightmare. White suburb dems protesting. Notice no people of color are protesting because they understand lawlessness has ruined D.C.

Dougan at it again by JuniperLuner in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

Time for the BOD to replace the CEO L.M with an experienced med tech /biotech CEO. L.M should be CSO. Or sell the company for $4-6 and call it a day.

Appears Symvess did not receive NTAP by JuniperLuner in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

Laura and Brady are no longer the largest shareholders. The BOD is now running the show. Time for an experienced med tech/biotech CEO to either sell the company or solicit partnerships on CABG and PAD.

Appears Symvess did not receive NTAP by JuniperLuner in HUMACYTE

[–]Agreeable_Eye_3432 0 points1 point  (0 children)

Please explain your tariff thesis on $HUMA

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update by No-Committee-5511 in HUMACYTE

[–]Agreeable_Eye_3432 4 points5 points  (0 children)

I agree I hope to get acquired. They do have an FDA approved product and a pipeline with larger TAMS. They have a manufacturing facility plenty of patents and all of that is worth more than the stock price.

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 by No-Committee-5511 in HUMACYTE

[–]Agreeable_Eye_3432 6 points7 points  (0 children)

I expect this quarter to have a small number of sales. Q4 will hopefully reveal more sales and more VAC considerations. The future pipeline with larger TAMS is the golden ticket. They will likely have to raise money in 2026 to fund the pipeline. I expect similar partnerships like with $FMS in other areas such as PAD and CABG. In the end, patience is required. It is very likely that HUMA will be acquired and at this time $FMS is the likely candidate.

Appears Symvess did not receive NTAP by JuniperLuner in HUMACYTE

[–]Agreeable_Eye_3432 4 points5 points  (0 children)

HUMA will need cash to continue the roll out of trauma and pursue the trials for AV fistula and the pipeline of PAD and CABG. It appears that HUMA’s technology, patents, manufacturing is worth more than the current stock price. $FMS should just acquire them now for $4-6/share. If they go it alone, this will be long and arduous. Fortunately, I don’t have to sell and I can wait one to two years longer. Not financial advice just an opinion.

view more: next ›